Effect of serum sample storage temperature on metabolomic and proteomic biomarkers.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 03 2022
Historique:
received: 08 12 2021
accepted: 08 03 2022
entrez: 18 3 2022
pubmed: 19 3 2022
medline: 6 5 2022
Statut: epublish

Résumé

Prospective biomarker studies can be used to identify biomarkers predictive of disease onset. However, if serum biomarkers are measured years after their collection, the storage conditions might affect analyte concentrations. Few data exists concerning which metabolites and proteins are affected by storage at - 20 °C vs - 80 °C. Our objectives were to document analytes affected by storage of serum samples at - 20 °C vs - 80 °C, and to identify those indicative of the storage temperature. We utilized liquid chromatography tandem mass spectrometry and Luminex to quantify 300 analytes from serum samples of 16 Finnish individuals with type 1 diabetes, with split-aliquot samples stored at - 80 °C and - 20 °C for a median of 4.2 years. Results were validated in 315 Finnish and 916 Scottish individuals with type 1 diabetes, stored at - 20 °C and at - 80 °C, respectively. After quality control, we analysed 193 metabolites and proteins of which 120 were apparently unaffected and 15 clearly susceptible to storage at - 20 °C vs - 80 °C. Further, we identified serum glutamate/glutamine ratio greater than 0.20 as a biomarker of storage at - 20 °C vs - 80 °C. The results provide a catalogue of analytes unaffected and affected by storage at - 20 °C vs - 80 °C and biomarkers indicative of sub-optimal storage.

Identifiants

pubmed: 35301383
doi: 10.1038/s41598-022-08429-0
pii: 10.1038/s41598-022-08429-0
pmc: PMC8930974
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4571

Subventions

Organisme : Chief Scientist Office
ID : ETM/47
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : Ref. ETM/47
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

Biochem J. 1995 Jan 1;305 ( Pt 1):17-20
pubmed: 7826325
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Diabetologia. 2018 May;61(5):996-1011
pubmed: 29520581
Clin Chem. 1993 Sep;39(9):1764-79
pubmed: 8375046
Clin Chem. 2006 Dec;52(12):2258-64
pubmed: 17068168
J Proteome Res. 2018 Jan 5;17(1):203-211
pubmed: 29064256
PLoS One. 2014 Feb 24;9(2):e89728
pubmed: 24586991
Int J Epidemiol. 2017 Jun 1;46(3):796-796i
pubmed: 28338705
Anal Chem. 2015 Apr 7;87(7):3800-5
pubmed: 25746059
Clin Chim Acta. 1974 May 17;52(3):335-41
pubmed: 4839092
Clin Nutr. 1991 Aug;10(4):193-8
pubmed: 16839918
Diabetologia. 2019 Sep;62(9):1616-1627
pubmed: 31222504
J Agric Food Chem. 1998 Feb 16;46(2):490-498
pubmed: 10554268
Nat Protoc. 2011 Jun 30;6(7):1060-83
pubmed: 21720319
OMICS. 2017 Sep;21(9):499-508
pubmed: 28873014
Diabet Med. 2000 Jan;17(1):7-14
pubmed: 10691153
EBioMedicine. 2016 Oct;12:309-314
pubmed: 27596149
Kidney Int. 1988 Jul;34(1):117-20
pubmed: 3172632
Metabolomics. 2021 Mar 11;17(3):31
pubmed: 33704583
Mol Oncol. 2014 Jun;8(4):840-58
pubmed: 24713096
Diabetes Care. 2005 Aug;28(8):2019-24
pubmed: 16043748
Diabetologia. 1993 Sep;36(9):835-42
pubmed: 8405755
Vox Sang. 2006 Jan;90(1):33-9
pubmed: 16359353
Proteome Sci. 2013 Mar 21;11(1):10
pubmed: 23518135
Metabolomics. 2016;12:96
pubmed: 27199628
J Pharm Biomed Anal. 2018 Jan 5;147:149-173
pubmed: 28823764
Analyst. 2014 Mar 7;139(5):1168-77
pubmed: 24443722
Blood Coagul Fibrinolysis. 2001 Jun;12(4):229-36
pubmed: 11460005
Crit Rev Biochem Mol Biol. 1991;26(1):1-52
pubmed: 1678690

Auteurs

Erkka Valo (E)

Folkhälsan Institute of Genetics, Folkhälsan Research Center, 00290, Helsinki, Finland.
Department of Nephrology, University of Helsinki and Helsinki University Hospital, 00290, Helsinki, Finland.
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00290, Helsinki, Finland.

Marco Colombo (M)

The Usher Institute, University of Edinburgh, Edinburgh, UK.

Niina Sandholm (N)

Folkhälsan Institute of Genetics, Folkhälsan Research Center, 00290, Helsinki, Finland.
Department of Nephrology, University of Helsinki and Helsinki University Hospital, 00290, Helsinki, Finland.
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00290, Helsinki, Finland.

Stuart J McGurnaghan (SJ)

The Usher Institute, University of Edinburgh, Edinburgh, UK.
Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

Luke A K Blackbourn (LAK)

Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

David B Dunger (DB)

Department of Paediatrics, University of Cambridge, Cambridge, UK.
Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Paul M McKeigue (PM)

The Usher Institute, University of Edinburgh, Edinburgh, UK.

Carol Forsblom (C)

Folkhälsan Institute of Genetics, Folkhälsan Research Center, 00290, Helsinki, Finland.
Department of Nephrology, University of Helsinki and Helsinki University Hospital, 00290, Helsinki, Finland.
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00290, Helsinki, Finland.

Per-Henrik Groop (PH)

Folkhälsan Institute of Genetics, Folkhälsan Research Center, 00290, Helsinki, Finland. per-henrik.groop@helsinki.fi.
Department of Nephrology, University of Helsinki and Helsinki University Hospital, 00290, Helsinki, Finland. per-henrik.groop@helsinki.fi.
Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 00290, Helsinki, Finland. per-henrik.groop@helsinki.fi.
Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia. per-henrik.groop@helsinki.fi.

Helen M Colhoun (HM)

Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK. helen.colhoun@ed.ac.uk.
Department of Public Health, NHS Fife, Kirkcaldy, UK. helen.colhoun@ed.ac.uk.

Charles Turner (C)

WellChild Laboratory, Evelina London Children's Hospital, Guy's and St Thomas' National Health Service Foundation Trust, London, UK.

R Neil Dalton (RN)

WellChild Laboratory, Evelina London Children's Hospital, Guy's and St Thomas' National Health Service Foundation Trust, London, UK. neil.dalton@gstt.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH